CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma

被引:2
|
作者
Shen, Mingfang [1 ]
Zhang, Yunfeng [1 ]
Tang, Lun [1 ]
Fu, Qinyan [1 ]
Zhang, Jiawei [2 ]
Xu, Yang [2 ]
Zeng, Hui [1 ]
Li, Yuan [1 ]
机构
[1] First Hosp Jiaxing, Dept Hematol, Jiaxing 314001, Zhejiang, Peoples R China
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Hematol, Hangzhou 310009, Zhejiang, Peoples R China
关键词
CDC6; Diffuse large B cell lymphoma; Cell cycle; Apoptosis; Prognosis; DNA-REPLICATION; CANCER; EXPRESSION; ACTIVATION; CHECKPOINT; INITIATION; PROTEINS;
D O I
10.1186/s12885-023-11186-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Cell division cycle 6 (CDC6) is a key licensing factor in the assembly of pre-replicative complexes at origins of replication. The role of CDC6 in the pathogenesis of in diffuse larger B-cell lymphoma (DLBCL) remains unknown. We aim to investigate the effects of CDC6 on the proliferation, apoptosis and cell cycle regulation in DLBCL cells, delineate its underlying mechanism, and to correlate CDC6 expression with clinical characteristics and prognosis of patients with DLBCL.Methods Initial bioinformatic analysis was performed to screen the potential role of CDC6 in DLBCL. Lentiviral constructs harboring CDC6 or shCDC6 was transfected to overexpress or knockdown CDC6 in SUDHL4 and OCI-LY7 cells. The cell proliferation was evaluated by CCK-8 assay, cell apoptosis was detected by Annexin-V APC/7-AAD double staining, and cell cycle was measured by flow cytometry. Real time quantitative PCR and western blot was used to characterize CDC6 expression and its downstream signaling pathways. The clinical data of DLBCL patients were retrospectively reviewed, the CDC6 expression in DLBCL or lymph node reactive hyperplasia tissues was evaluated by immunohistochemistry.Results In silico data suggest that CDC6 overexpression is associated with inferior prognosis of DLBCL. We found that CDC6 overexpression increased SUDHL4 or OCI-LY7 cell proliferation, while knockdown of CDC6 inhibited cell proliferation in a time-dependent manner. Upon overexpression, CDC6 reduced cells in G1 phase and did not affect cell apoptosis; CDC6 knockdown led to significant cell cycle arrest in G1 phase and increase in cell apoptosis. Western blot showed that CDC6 inhibited the expression of INK4, E-Cadherin and ATR, accompanied by increased Bcl-2 and deceased Bax expression. The CDC6 protein was overexpressed DLBCL compared with lymph node reactive hyperplasia, and CDC6 overexpression was associated with non-GCB subtype, and conferred poor PFS and OS in patients with DLBCL.Conclusion CDC6 promotes cell proliferation and survival of DLBCL cells through regulation of G1/S cell cycle checkpoint and apoptosis. CDC6 is overexpressed and serves as a novel prognostic marker in DLBCL.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] A 6-lncRNA signature predicts prognosis of diffuse large B-cell lymphoma
    Gao, Hongyu
    Wu, Bin
    Jin, Hong
    Yang, Wei
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2021, 35 (06) : 1 - 12
  • [22] Diffuse large B-cell lymphoma - Molecular heterogeneity of diffuse large B-cell lymphoma
    Gascoyne, RD
    HEMATOLOGY JOURNAL, 2004, 5 : S144 - S148
  • [23] MicroRNA-26a/b Regulate DNA Replication Licensing, Tumorigenesis, and Prognosis by Targeting CDC6 in Lung Cancer
    Zhang, Xin
    Xiao, Dakai
    Wang, Ziyi
    Zou, Yongxin
    Huang, Liyan
    Lin, Weixuan
    Deng, Qiuhua
    Pan, Hui
    Zhou, Jiangfen
    Liang, Chun
    He, Jianxing
    MOLECULAR CANCER RESEARCH, 2014, 12 (11) : 1535 - 1546
  • [24] DNA replication licensing in peripheral B-cell lymphoma
    Obermann, EC
    Eward, KL
    Dogan, A
    Paul, EA
    Loddo, M
    Munson, P
    Williams, GH
    Stoeber, K
    JOURNAL OF PATHOLOGY, 2005, 205 (03): : 318 - 328
  • [25] Expression of BMI-1 is a poor prognostic factor in diffuse large B-cell lymphoma
    Hukku, S.
    Almiski, S.
    Vakil, H.
    Kurre, A.
    Levi, E.
    LABORATORY INVESTIGATION, 2008, 88 : 257A - 258A
  • [26] Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients
    Manfroi, B.
    Moreaux, J.
    Righini, C.
    Ghiringhelli, F.
    Sturm, N.
    Huard, B.
    BLOOD CANCER JOURNAL, 2018, 8
  • [27] Expression of BMI-1 is a poor prognostic factor in diffuse large B-Cell lymphoma
    Hukku, S.
    Almiski, S.
    Vakil, H.
    Kurrer, A.
    Levi, E.
    MODERN PATHOLOGY, 2008, 21 : 257A - 258A
  • [28] Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma
    You, Hua
    Xu-Monette, Zijun Y.
    Wei, Li
    Nunns, Harry
    Nagy, Mate L.
    Bhagat, Govind
    Fang, Xiaosheng
    Zhu, Feng
    Visco, Carlo
    Tzankov, Alexandar
    Dybkaer, Karen
    Chiu, April
    Tam, Wayne
    Zu, Youli
    Hsi, Eric D.
    Hagemeister, Fredrick B.
    Huh, Jooryung
    Ponzoni, Maurilio
    Ferreri, Andres J. M.
    Moller, Michael B.
    Parsons, Benjamin M.
    Van Krieken, J. Han
    Piris, Miguel A.
    Winter, Jane N.
    Li, Yong
    Au, Qingyan
    Xu, Bing
    Albitar, Maher
    Young, Ken H.
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [29] High PTX3 expression is associated with a poor prognosis in diffuse large B-cell lymphoma
    Carreras, Joaquim
    Kikuti, Yara Yukie
    Hiraiwa, Shinichiro
    Miyaoka, Masashi
    Tomita, Sakura
    Ikoma, Haruka
    Ito, Atsushi
    Kondo, Yusuke
    Itoh, Johbu
    Roncador, Giovanna
    Martinez, Antonio
    Colomo, Lluis
    Hamoudi, Rifat
    Ando, Kiyoshi
    Nakamura, Naoya
    CANCER SCIENCE, 2022, 113 (01) : 334 - 348
  • [30] Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients
    B. Manfroi
    J. Moreaux
    C. Righini
    F. Ghiringhelli
    N. Sturm
    B. Huard
    Blood Cancer Journal, 8